The use of mtt [3-(4, 5-dimethyl-2-thiazolyl) -2, 5-diphenyl -2h- tetrazolium bromide]-reduction as an indicator of the effects of strain-specific, polyclonal rabbit antisera on Candida albicans and C. krusei

Indian Journal of Medical Microbiology

Volumn 25, Issue 3, 2007, Pages 267-271

  Arseculeratne, S ^a   Atapattu, D ^a   Kumarasiri, R ^a   Perera, D ^a   Ekanayake, D ^a   Rajapakse, J ^a  

^a UNIVERSITY OF PERADENIYA   (Sri Lanka)

Author keywords

Candida albicans; Candida krusei; Complement; In vitro; Strain specific antibody; Viability

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; RABBIT ANTISERUM;

ARTICLE; CANDIDA ALBICANS; CANDIDA KRUSEI; CELL FREE SYSTEM; FUNGAL STRAIN; GUINEA PIG; HOST CELL; IMMUNITY; INNER CELL MASS; NONHUMAN; PHAGOCYTOSIS; RABBIT; SERUM;

EID: 34848854590     PISSN: 02550857     EISSN: 02550857     Source Type: Journal    
DOI: 10.4103/0255-0857.34773     Document Type: Article

References (18)

1. Chilgren RA, Hong R, Quie PG. Human serum interactions with Candida albicans. J Immunol 1968;101:128-32.
2. Moragues MD, Omaetxebarria MJ, Elguezabal N, Sevilla MJ, Conti S, Polonelli L, et al. A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-Candida albicans activities. Infect Immun 2003;71:5273-9.
3. Challacombe S. Immunity in Oral Candidosis. In: Samaranayake LP, MacFarlane TW, editors. Oral Candidosis, Wright: London; 1990. p. 104-23, 113, 110.
4. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun 1995;63:4211-8.
5. Greenfield RA. Host defence system interactions with Candida. J Med Vet Mycol 1992;30:89-104.
6. Levitz SM, Diamond RD. A rapid colorimetric assay of fungal viability with the Tetrazolium salt MTT. J Infect Dis 1985;152:938-45.
7. Jahn B, Martin E, Stueben A, Bhakdi S. Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-Thaizolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. J Clin Microbiol 1995;33:661-7.
8. Arseculeratne SN, Kumarasiri PV, Rajapakse RP, Perera NA, Arseculeratne G, Atapattu DN. Anti-rhinosporidial antibody levels in patients with rhinosporidiosis and in asymptomatic persons in Sri Lanka. Mycopathologia 2004;158:157-64.
9. Arseculeratne SN, Atapattu DN. The assessment of the viability of the endospores of Rhinosporidium seeberi with MTT (3- [4,5-dimethyl-2- thiazolyl] 2,5-diphenyl-2H-tetrazolium bromide). Mycological Res 2004;108:1423-30.
10. Murphy JW. Mechanisms of Natural Resistance to human pathogenic fungi. Annu Rev Microbiol 1991;45:509-38.
11. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004;4:1-23.
12. Baum GL, Artis D. Growth inhibition of Cryptococcus neoformans by cell-free human serum. Am J Med Sci 1961;241:613-6.
13. Lehrer RI, Cline MJ. Interaction with Candida albicans with human leucocytes and serum. J Bact 1969;98:996-1004.
14. Arseculeratne SN, Atapattu DN, Eriyagama NB. Human anti-rhinosporidial antibody does not cause metabolic inactivation or morphological damage in endospores of Rhinosporidium seeberi in vitro. Indian J Med Microbiol 2005;23:14-9.
15. Kozel TR. Activation of the complement system by pathogenic fungi. Clin Microbiol Rev 1996;9:34-46.
16. Levitz SM. Overview of host defenses in fungal infections. Clin Infect Dis 1992;14:S37-42.
17. Shoham S, Levitz SM. Immune responses to fungi. In: Rich RR, Fleicher TA, Shearer WB, Kotzin BL, Schroeder HW Jr, editors. Clinical Immunology. Principles and Practice. vol. 1. Mosby: New York; 2001. p. 31.1-31.7.
18. Han Y, Cutler JE. Antibody response that protects against disseminated Candidiasis. Infect Immun 1995;63:2714-9.